Crohn's disease: Step up or top down therapy

Stephen B. Hanauer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Abstract

The concept of a 'step-up' or 'top-down' approach to the treatment of Crohn's disease has evolved from the impact of novel anti-TNF (anti-tumour necrosis factor) therapies that have been effective for patients who are refractory to other medical treatments. In addition, the potential to produce mucosal healing with anti-TNF treatments without the well-recognized systemic complications of glucocorticoid therapy has created debate as to whether earlier, more aggressive, therapies should be advocated. This controversy arises at a time when the concept of sequential therapy to induce and maintain remissions for Crohn's disease has begun to be accepted and precedes our ability to define the concept of disease modification or predict the natural history of Crohn's disease based upon clinical, pathological, molecular orgenetic criteria. Evidence for therapeutic efficacy in Crohn's disease is presented as a prologue to considerations necessary to determine the benefits and risks of early aggressive treatment versus sequential approaches based upon disease severity.

Original languageEnglish (US)
Pages (from-to)131-137
Number of pages7
JournalBailliere's Best Practice and Research in Clinical Gastroenterology
Volume17
Issue number1
DOIs
StatePublished - Feb 2003

Keywords

  • Clinical trials
  • Crohn's disease
  • Inflammatory bowel disease

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Crohn's disease: Step up or top down therapy'. Together they form a unique fingerprint.

Cite this